Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
13.16
0.39 (3.05%)
May 20, 2022 4:00 PM EDT - Market closed
Company Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc.
Country | United States |
Founded | 2018 |
IPO Date | Jun 30, 2021 |
Industry | Biotechnology |
Sector | Health Care |
Employees | 18 |
Contact Details
Address: 930 Winter Street Waltham, MA 02116 United States | |
Phone | 617 443 2400 |
Stock Details
Ticker Symbol | AVTE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | US Dollars |
IPO Price | $14.00 |
CIK Code | 1798749 |
Key Executives
Name | Position |
---|---|
Timothy P. Noyes M.B.A. | Chief Executive Officer and Director |
Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer and Secretary |
George A. Eldridge | Chief Financial Officer and Treasurer |
Hunter Gillies M.D. | Chief Medical Officer |
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Development Officer |
Timothy J. Pigot | Senior Vice President of Commercial |
Donna Dea | Head of Regulatory Affairs |
Dr. Marinus Verwijs Ph.D. | Senior Vice President of CMC |
Sue Fischer | Senior Vice President of Development Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 16, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
May 16, 2022 | 8-K | Current report |
May 5, 2022 | SC 13D/A | General statement of acquisition of beneficial ownership |
Apr 29, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2022 | DEF 14A | Other definitive proxy statements |
Apr 29, 2022 | 8-K | Current report |
Apr 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Mar 30, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 30, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
Mar 30, 2022 | 8-K | Current report |
View All SEC Filings |